By what route is Xolair (omalizumab) administered?

Xolair (omalizumab) is administered subcutaneously, meaning it is injected into the fatty tissue under the skin. This route allows the medication to be absorbed into the bloodstream gradually, which is essential for its effectiveness in treating conditions like asthma and chronic idiopathic urticaria.

Administering Xolair subcutaneously minimizes potential systemic side effects and provides a more consistent release of the medication compared to intravenous (IV) administration. It is typically given in a clinical setting, with the healthcare provider determining the appropriate dosage based on the patient's weight and specific condition.

The other methods, such as aerosolized delivery or intramuscular injections, are not suitable for Xolair due to its formulation and the need for controlled dosing and gradual absorption.